Drug
Avatrombopag
Avatrombopag: highest development phase Phase 2/3, developed by Eisai, Swedish Orphan Biovitrum. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Eisai, Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| Avatrombopag 20 mg Oral Tablet NCT07786922 | Phase 2/3 | Aplastic Anemia |
| Avatrombopag NCT02809768 | Phase 1 | Healthy Participants |
Latest
No recent events.
Follow Avatrombopag on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.